Please assess the completion status of the following clinical trial:

Trial Title: Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria~* EDSS score between 0 and 5.0 at baseline~Exclusion Criteria:~• Primary progressive multiple sclerosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Interferon beta-1a (Type: ACTIVE_COMPARATOR): Participants received 30 µg interferon beta-1a by intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally once a day until the last participant had been treated for 12 months.
- Ozanimod 0.5 mg (Type: EXPERIMENTAL): Participants received ozanimod 0.5 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.
- Ozanimod 1 mg (Type: EXPERIMENTAL): Participants received ozanimod 1 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).